Clinical trial
US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With…
NCT00282295 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00282295 |
|---|---|
| Title | US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease |
| Official title | Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acellular Pertussis, Tetanus, Diphtheria |
| Intervention type | Biological |
| Interventions | Boostrix®, Menactra™ |
| Enrollment | 1,344 |
| Start date | Jan 25, 2006 |
| Primary completion | Aug 8, 2006 |
| Completion | Aug 8, 2006 |
| First posted | Jan 26, 2006 |
| Last update posted | Aug 17, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: